Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS)

Presse Medicale

Volumn 42, Issue 6 PART2, 2013, Pages

  van Doorn, Pieter A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE ANTIBODY; GANGLIOSIDE GM1 ANTIBODY; GANGLIOSIDE GQ 1B ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; STEROID;

ACUTE DISEASE; ACUTE INFLAMMATORY DEMYELINATING POLYNEUROPATHY; ACUTE MOTOR AXONAL NEUROPATHY; ARTIFICIAL VENTILATION; AUTONOMIC DYSFUNCTION; CEREBROSPINAL FLUID EXAMINATION; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; DETERIORATION; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; ELECTROMYOGRAM; ELECTROMYOGRAPHY; FATIGUE; FUNCTIONAL STATUS; GUILLAIN BARRE SYNDROME; HEALTH CARE QUALITY; HEART FUNCTION; HOSPITAL ADMISSION; HUMAN; IATROGENIC DISEASE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INFECTION; INFECTION PREVENTION; INTENSIVE CARE UNIT; MOTOR PERFORMANCE; OUTCOME ASSESSMENT; PAIN; PATHOPHYSIOLOGY; PATIENT MONITORING; PLASMAPHERESIS; POLYNEUROPATHY; PROGNOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; RATING SCALE; RESPIRATORY FUNCTION; RETREATMENT; SHORT SURVEY; STEROID THERAPY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 84879173384     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2013.02.328     Document Type: Short Survey

References (54)

1. Guillain G., Barré J.A., Strohl A. Sur un syndrome de radiculo-névrite avec hyperalbuminose du liquide céphalorachidien sans réaction cellulaire. Remarques sur les caractères cliniques et graphiques des réflexes tendineux. Bull Soc Med Hop Paris 1916, 28:1462-1470.
2. Landry O. Note sur la paralyse ascendente aiguë. Gazette Hebdomadaire Med Chir 1859, 6:472-474. [486-8].
3. Hughes R.A., Cornblath D.R. Guillain-Barré syndrome. Lancet 2005, 366:1653-1666.
4. Yuki N., Hartung H.P. Guillain-Barré syndrome. N Engl J Med 2012, 366:2294-2304.
5. Jacobs B.C., Rothbarth P.H., Van Der Meché F.G., Herbrink P., Schmitz P.I., de Klerk M.A., et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 1998, 51:1110-1115.
6. Hadden R.D., Karch H., Hartung H.P., Zielasek J., Weissbrich B., Schubert J., et al. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology 2001, 56:758-765.
7. Asbury A.K., Cornblath D.R. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990, 27(Suppl.):S21-S24.
8. Bernsen R.A., de Jager A.E., Schmitz P.I., Van Der Meché F.G. Residual physical outcome and daily living 3 to 6years after Guillain-Barré syndrome. Neurology 1999, 53:409-410.
9. Bernsen R.A., Jacobs H.M., de Jager A.E., Van Der Meché F.G. Residual health status after Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1997, 62:637-640.
10. van Doorn P.A., Ruts L., Jacobs B.C. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008, 7:939-950.
11. Ruts L., Drenthen J., Jongen J.L., Hop W.C., Visser G.H., Jacobs B.C., et al. Pain in Guillain-Barré syndrome: a long-term follow-up study. Neurology 2010, 75:1439-1447.
12. Roodbol J., de Wit M.C., Walgaard C., de Hoog M., Catsman-Berrevoets C.E., Jacobs B.C. Recognizing Guillain-Barré syndrome in preschool children. Neurology 2011, 76:807-810.
13. Hadden R.D., Cornblath D.R., Hughes R.A., Zielasek J., Hartung H.P., Toyka K.V., et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol 1998, 44:780-788.
14. Willison H.J. The immunobiology of Guillain-Barré syndromes. J Peripher Nerv Syst 2005, 10:94-112.
15. Willison H.J. Ganglioside complexes: new autoantibody targets in Guillain-Barré syndromes. Nat Clin Pract Neurol 2005, 1:2-3.
16. Kusunoki S., Kaida K., Ueda M. Antibodies against gangliosides and ganglioside complexes in Guillain-Barré syndrome: new aspects of research. Biochim Biophys Acta 2008, 1780:441-444.
17. Yuki N. Fisher syndrome and Bickerstaff brainstem encephalitis (Fisher-Bickerstaff syndrome). J Neuroimmunol 2009, 215:1-9.
18. Yuki N. Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni isolated from patients with Guillain-Barré syndrome and Miller Fisher syndrome. J Infect Dis 1997, 176(Suppl.2):S150-S153.
19. Yuki N. Anti-ganglioside antibody and neuropathy: review of our research. J Peripher Nerv Syst 1998, 3:3-18.
20. Ang C.W., Jacobs B.C., Laman J.D. The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol 2004, 25:61-66.
21. Sejvar J.J., Kohl K.S., Gidudu J., Amato A., Bakshi N., Baxter R., et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011, 29:599-612.
22. Hughes R.A., Wijdicks E.F., Benson E., Cornblath D.R., Hahn A.F., Meythaler J.M., et al. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol 2005, 62:1194-1198.
23. Walgaard C., Lingsma H.F., Ruts L., Drenthen J., van Koningsveld R., Garssen M.J., et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol 2010, 67:781-787.
24. The Guillain-Barré syndrome Study Group Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985, 35:1096-1104.
25. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987, 22:753-761.
26. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997, 349:225-230.
27. Hughes R.A., Swan A.V., Raphael J.C., Annane D., van Koningsveld R., van Doorn P.A. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 2007, 130:2245-2257.
28. Raphael J.C., Chevret S., Hughes R.A., Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2012, 7:CD001798.
29. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 1997, 41:298-306.
30. Van Der Meché F.G., Schmitz P.I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 1992, 326:1123-1129.
31. Hughes R.A., Swan A.V., van Doorn P.A. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2012, 7:CD002063.
32. Guillain-Barré Syndrome Steroid Trial Group Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993, 341:586-590.
33. van Koningsveld R., Schmitz P.I., Meché F.G., Visser L.H., Meulstee J., van Doorn P.A. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 2004, 363:192-196.
34. Hughes R.A., van Doorn P.A. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev 2012, 8:CD001446.
35. Garssen M.P., van Koningsveld R., van Doorn P.A., Merkies I.S., Scheltens-de B.M., van Leusden J.A., et al. Treatment of Guillain-Barré syndrome with mycophenolate mofetil: a pilot study. J Neurol Neurosurg Psychiatry 2007, 78:1012-1013.
36. Overell J.R., Hsieh S.T., Odaka M., Yuki N., Willison H.J. Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Cochrane Database Syst Rev 2007, 1:CD004761.
37. Mori M., Kuwabara S., Yuki N. Fisher syndrome: clinical features, immunopathogenesis and management. Expert Rev Neurother 2012, 12:39-51.
38. Mori M., Kuwabara S. Fisher syndrome. Curr Treat Options Neurol 2011, 13:71-78.
39. Mori M., Kuwabara S., Fukutake T., Hattori T. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology 2007, 68:1144-1146.
40. Farcas P., Avnun L., Frisher S., Herishanu Y.O., Wirguin I. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome. Lancet 1997, 350:1747.
41. Kuitwaard K., de Gelder J., Tio-Gillen A.P., Hop W.C., van Gelder T., van Toorenenbergen A.W., et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol 2009, 66:597-603.
42. Walgaard C., Lingsma H.F., Ruts L., van Doorn P.A., Steyerberg E.W., Jacobs B.C. Early recognition of poor prognosis in Guillain-Barré syndrome. Neurology 2011, 76:968-975.
43. Ruts L., van Koningsveld R., van Doorn P.A. Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment-related fluctuations. Neurology 2005, 65:138-140.
44. Kleyweg R.P., Van Der Meché F.G. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry 1991, 54:957-960.
45. Ruts L., Drenthen J., Jacobs B.C., van Doorn P.A. Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome: a prospective study. Neurology 2010, 74:1680-1686.
46. Ruts L., Rico R., Koningsveld R., van J.D., Botero J., Meulstee I., et al. Pain accompanies pure motor Guillain-Barré syndrome. J Peripher Nerv Syst 2008, 13:305-306.
47. Ruts L., van Doorn P.A., Lombardi R., Haasdijk E.D., Penza P., Tulen J.H., et al. Unmyelinated and myelinated skin nerve damage in Guillain-Barré syndrome: correlation with pain and recovery. Pain 2012, 153:399-409.
48. Merkies I.S., Schmitz P.I., Samijn J.P., Van Der Meché F.G., van Doorn P.A. Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 1999, 53:1648-1654.
49. Garssen M.P., Bussmann J.B., Schmitz P.I., Zandbergen A., Welter T.G., Merkies I.S., et al. Physical training and fatigue, fitness, and quality of life in Guillain-Barré syndrome and CIDP. Neurology 2004, 63:2393-2395.
50. Durand M.C., Porcher R., Orlikowski D., Aboab J., Devaux C., Clair B., et al. Clinical and electrophysiological predictors of respiratory failure in Guillain-Barré syndrome: a prospective study. Lancet Neurol 2006, 5:1021-1028.
51. van Koningsveld R., Steyerberg E.W., Hughes R.A., Swan A.V., van Doorn P.A., Jacobs B.C. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol 2007, 6:589-594.
52. Halstead S.K., Zitman F.M., Humphreys P.D., Greenshields K., Verschuuren J.J., Jacobs B.C., et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008, 131:1197-1208.
53. Lingsma H., Roozenbeek B., Steyerberg E. Covariate adjustment increases statistical power in randomized controlled trials. J Clin Epidemiol 2010, 63:1391. [author reply: 1392-3].
54. van Nes S.I., Faber C.G., Merkies I.S.J. Outcome measures in immune-mediated neuropathies: the need to standardize their use and to understand the clinimetric essentials. J Peripher Nerv Syst 2008, 13:136-147.